Vardenafil (Levitra/Staxyn) FAERS Safety Signals: What the Post-Market Data Show

What Is FAERS and Why Does It Matter for Vardenafil?

The FDA Adverse Event Reporting System (FAERS) is a spontaneous-reporting pharmacovigilance database that collects reports from manufacturers, healthcare providers, and patients after a drug reaches the market. For a drug like vardenafil, which reached approval in 2003 and has since accumulated more than two decades of real-world exposure, FAERS data supplement clinical-trial findings with signals that only become visible in large, heterogeneous populations.

How FAERS Reports Are Generated

Manufacturers are legally required to submit 15-day expedited reports for serious unexpected adverse events and periodic safety update reports (PSURs) at set intervals. Healthcare providers and patients submit voluntarily. Because reporting is not mandatory for most parties, FAERS undercounts absolute event rates, but it excels at detecting relative signals across drug classes.

Disproportionality analyses, specifically the Reporting Odds Ratio (ROR) and Proportional Reporting Ratio (PRR), are used to flag whether a drug-event pair appears more often than would be expected by chance across the entire database. The FDA's Sentinel System supplements FAERS by querying claims data from more than 100 million insured Americans to validate signals with actual exposure denominators.

Vardenafil's Market History and Reporting Volume

Levitra received FDA approval on August 19, 2003, for the treatment of erectile dysfunction in adult men. Staxyn, the orally disintegrating tablet formulation (10 mg), received approval on June 29, 2010. Because sildenafil (Viagra) entered the PDE5 market five years earlier in 1998, vardenafil's FAERS dataset is informative both as a standalone record and as a comparator within the drug class. FDA approval records are searchable via Drugs@FDA.

Current FDA-Approved Label: Key Safety Language

The current Levitra prescribing information, last substantively revised with class-wide updates, contains several sections that directly reflect post-market FAERS signals and FDA regulatory actions.

Contraindications

The label carries an absolute contraindication against co-administration with nitrates in any form, including nitroglycerin tablets, patches, sprays, isosorbide mononitrate, and isosorbide dinitrate. This contraindication applies regardless of dosing frequency. The pharmacodynamic basis is additive vasodilation: vardenafil inhibits PDE5 in vascular smooth muscle, and nitrates increase cyclic GMP independently, producing hypotension that may be severe and sudden.

Vardenafil is also contraindicated in patients taking soluble guanylate cyclase (sGC) stimulators such as riociguat, because both agents lower systemic vascular resistance through overlapping cGMP pathways. The FDA's drug-interaction guidance for PDE5 inhibitors covers these mechanisms in detail.

Warnings and Precautions Added After Approval

Several warnings were added to the vardenafil label after the 2003 approval date, reflecting FAERS signals confirmed through additional investigation.

QT Prolongation (2005). A dedicated thorough QT/QTc study showed that vardenafil 10 mg prolonged the QTc interval by a mean of 8 milliseconds and vardenafil 80 mg (a supratherapeutic dose) prolonged it by 10 milliseconds. The label was updated in 2005 to warn against use in patients with congenital long-QT syndrome, in patients taking Class IA antiarrhythmics (quinidine, procainamide) or Class III antiarrhythmics (amiodarone, sotalol), and in patients with known QT prolongation. The FDA's QT prolongation guidance is available here.

Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION). Post-marketing reports, first accumulating in FAERS after 2005, described sudden vision loss in men taking PDE5 inhibitors. The FDA issued a class-wide safety communication in 2005 and required NAION language in all PDE5 inhibitor labels. The warning notes that most cases involved patients with pre-existing risk factors including low cup-to-disc ratio ("crowded disc"), hypertension, diabetes, coronary artery disease, hyperlipidemia, age over 50 years, and smoking. Patients should stop vardenafil and seek immediate care if sudden vision loss occurs in one or both eyes. The 2005 FDA public health advisory on PDE5 inhibitors and NAION is archived here.

Sudden Hearing Loss. In October 2007, the FDA required all PDE5 inhibitor manufacturers to update labeling to include a warning about sudden decrease or loss of hearing, sometimes accompanied by tinnitus and dizziness. FAERS contained 29 case reports of sudden hearing loss associated with PDE5 inhibitors at the time of the regulatory action. The October 2007 FDA safety communication is available here.

FAERS Signal Categories for Vardenafil

Post-market surveillance for vardenafil has produced reproducible signals across five major categories. Each reflects a different physiological mechanism.

Cardiovascular Events

Cardiovascular adverse events represent the largest FAERS category for vardenafil by volume. The events include myocardial infarction, angina, cardiac arrest, and sudden cardiac death. Interpreting these reports requires context: erectile dysfunction itself is independently associated with cardiovascular disease, and many men taking vardenafil carry significant baseline cardiac risk.

The Princeton Consensus Guidelines (third iteration published in 2012) stratified men with ED into low, intermediate, and high cardiac risk categories to guide PDE5 inhibitor prescribing. Men in the high-risk category, including those with unstable angina, recent myocardial infarction within 2 weeks, uncontrolled hypertension, or advanced heart failure, should not receive vardenafil until cardiac status is stabilized. The Princeton III Consensus guidelines on sexual activity and cardiac risk are summarized at PubMed.

FAERS reports have not established a causal link between vardenafil and de novo myocardial infarction in men without pre-existing coronary disease. The signal persists because the population using PDE5 inhibitors overlaps substantially with the population at risk for acute cardiac events.

Hypotension: Nitrate and Alpha-Blocker Interactions

Clinically significant hypotension is the adverse event with the clearest pharmacodynamic explanation in the vardenafil FAERS dataset. Two drug classes dominate:

Nitrates. Co-administration with organic nitrates produces additive reductions in systemic vascular resistance. In a controlled pharmacodynamic study, vardenafil 20 mg administered 24 hours after a single dose of sublingual nitroglycerin 0.4 mg still produced a mean maximum decrease in standing systolic blood pressure of 6.2 mmHg compared with placebo. For this reason, the label specifies that vardenafil is contraindicated with all nitrate preparations regardless of timing. Pharmacokinetic and pharmacodynamic interactions are detailed in the FDA label.

Alpha-blockers. Vardenafil combined with alpha-adrenergic antagonists (used for benign prostatic hyperplasia or hypertension) can produce symptomatic hypotension. The interaction is most pronounced with tamsulosin and doxazosin. The label specifies initiating vardenafil at 5 mg in patients already stabilized on alpha-blockers, and initiating alpha-blockers at the lowest dose in patients already taking vardenafil.

Priapism

Vardenafil FAERS contains reports of priapism, defined as erection lasting more than 4 hours. The proposed mechanism involves prolonged smooth-muscle relaxation in penile corpora cavernosa due to sustained cGMP elevation. Cases have occurred in patients with sickle cell disease, multiple myeloma, and leukemia, all conditions that independently increase priapism risk. The label instructs patients to seek emergency care for any erection lasting more than 4 hours, because delay beyond 12 to 24 hours risks ischemic injury and permanent erectile dysfunction.

Vision Changes and NAION

The NAION signal, first identified in the class-wide FAERS review of 2005, prompted a dedicated epidemiological investigation. A case-crossover study published in the British Journal of Urology International found that PDE5 inhibitor use within the 5-day window before NAION onset was associated with a two-fold increased incidence compared with use outside that window. Relevant surveillance data are indexed at PubMed. Absolute risk remains low, but patients with a prior NAION episode in one eye should not use vardenafil because of the risk to the fellow eye.

Sudden Hearing Loss

The FDA's October 2007 label update for sudden hearing loss was based on 29 post-marketing FAERS reports across the PDE5 inhibitor class. Individual vardenafil reports described unilateral sudden sensorineural hearing loss, in some cases accompanied by tinnitus and vertigo, occurring within hours of dosing. The mechanism may involve PDE5 expression in cochlear microvasculature. The FDA safety update is archived here.

Phase III Clinical Trial Safety Data Supporting the FAERS Context

FAERS signals do not arise in a vacuum. Understanding their clinical weight requires comparing them with the controlled-trial safety database established before approval.

The Key Porst et al. 2003 Trial

Porst and colleagues published the key dose-finding efficacy and safety study for vardenafil in 2003, enrolling 805 men with erectile dysfunction across multiple centers. Vardenafil 5 mg, 10 mg, and 20 mg were compared with placebo over 12 weeks. The most common adverse events in the vardenafil arms were flushing (reported in 9% to 11% of patients), headache (14% to 17%), rhinitis (9% to 12%), and dyspepsia (4% to 6%). Serious cardiovascular events were numerically balanced between active drug and placebo groups. Porst H et al., Int J Impot Res 2003.

This safety profile established the baseline against which subsequent FAERS reports would be interpreted. Events appearing in FAERS at higher-than-expected rates relative to the trial database warranted regulatory action; events appearing at rates consistent with background cardiovascular risk in an ED population required more cautious interpretation.

ASSESS-1 and ASSESS-2 Trials

The ASSESS trials evaluated vardenafil in diabetic men with erectile dysfunction, a population with higher baseline cardiovascular risk and more comorbidities. Across both trials, the adverse-event profile was consistent with the general population data from Porst et al. Flushing, headache, and rhinitis dominated. No excess serious cardiovascular events were observed compared with placebo. ASSESS-1 data are indexed at PubMed. ASSESS-2 data are indexed at PubMed.

Long-Term Open-Label Extension Data

A long-term open-label extension study of vardenafil followed patients for up to 2 years of continuous treatment. The most commonly reported treatment-emergent adverse event remained flushing, occurring in approximately 10% of patient-years of exposure. No new safety signals emerged that had not already been identified in the short-term phase III program or through FAERS monitoring. Long-term extension safety data are available at PubMed.

Staxyn-Specific Safety Considerations

Staxyn (vardenafil 10 mg orally disintegrating tablet) received a separate NDA review in 2010. Because it dissolves on the tongue without water and is absorbed through the buccal mucosa in part, its pharmacokinetic profile differs from Levitra tablets. Peak plasma concentration (Cmax) for Staxyn 10 mg is approximately 21% higher than for Levitra 10 mg under fasting conditions, and the area under the curve (AUC) is approximately 11% higher.

This difference has clinical safety relevance. The Staxyn prescribing information specifically states that Staxyn and Levitra are not interchangeable on a milligram-for-milligram basis and that patients should not switch between formulations without physician guidance. The higher Cmax may increase the likelihood of vasodilatory adverse events such as flushing, headache, and dizziness.

Staxyn contains sorbitol as an excipient. Men with hereditary fructose intolerance should not use this formulation, a contraindication not applicable to standard Levitra tablets. FDA approval package for Staxyn is available via Drugs@FDA.

Drug Interactions: The FAERS-Informed Prescribing Checklist

Vardenafil is metabolized primarily by CYP3A4, with a minor contribution from CYP3A5 and CYP2C9. Strong CYP3A4 inhibitors produce clinically meaningful increases in vardenafil exposure. The FDA drug-interaction table is maintained here.

CYP3A4 Inhibitors

• Ritonavir (strong inhibitor): co-administration is contraindicated because ritonavir increased vardenafil AUC by 49-fold in a pharmacokinetic study. Patients taking ritonavir should not receive vardenafil.
• Indinavir, saquinavir (strong inhibitors): dose reduction to 2.5 mg per 72 hours is required.
• Ketoconazole 400 mg (strong inhibitor): increased vardenafil AUC approximately 10-fold; dose reduction to 2.5 mg per day is required.
• Ketoconazole 200 mg or erythromycin (moderate inhibitors): increased vardenafil AUC approximately 4-fold; dose reduction to 5 mg per day is recommended.

QT-Prolonging Agents

Co-administration with Class IA or Class III antiarrhythmics is contraindicated given the additive QT prolongation risk established in the thorough QT study. Men taking these antiarrhythmics for atrial fibrillation or ventricular arrhythmias should not receive vardenafil. Alternative ED management strategies should be discussed with the treating cardiologist.

Antihypertensives

Beyond alpha-blockers, vardenafil produces additive blood pressure lowering when combined with amlodipine, enalapril, and metoprolol. The mean additional decreases in supine systolic blood pressure with these combinations were 3 to 5 mmHg. These interactions do not typically require dose modification but warrant patient counseling about dizziness on standing. These interaction data are summarized in the FDA-approved label.

Special Populations: FAERS Signal Interpretation by Subgroup

Men with Diabetes

Diabetic men have a higher prevalence of cardiovascular autonomic neuropathy, which may blunt compensatory tachycardia during vardenafil-induced vasodilation. The ASSESS trials showed no excess hypotension events in diabetic patients, but FAERS reports include cases of symptomatic postural hypotension in men with long-standing type 2 diabetes who were also taking antihypertensive therapy. The ADA Standards of Medical Care in Diabetes address ED management in diabetic men.

Older Adults

Men aged 65 years and older show a 52% increase in vardenafil AUC compared with younger men (65 years vs. 45 years in pharmacokinetic studies), reflecting reduced hepatic CYP3A4 activity and decreased plasma protein binding. The label recommends starting at 5 mg in men over 65, with titration based on tolerability. FAERS reports in older adults more frequently include syncope and falls, likely reflecting the combination of baseline orthostatic instability and vasodilatory drug effect.

Renal Impairment

No dose adjustment is required for any degree of renal impairment because vardenafil is not renally cleared to a meaningful extent. However, FAERS contains cases in dialysis patients where increased drug exposure appeared to contribute to prolonged adverse effects. Renal pharmacokinetics are addressed in the FDA label.

Hepatic Impairment

Child-Pugh class B hepatic impairment increases vardenafil AUC by approximately 160%, requiring a starting dose of 5 mg and a maximum dose of 10 mg. Vardenafil is not studied in Child-Pugh class C patients and should not be used in this group.

FDA Sentinel and EMA Surveillance: Complementary Data Sources

The FDA Sentinel System, which queries electronic health records and claims data from more than 100 million Americans, has been used to evaluate PDE5 inhibitor safety signals in ways that FAERS spontaneous reports cannot support. Sentinel analyses allow calculation of actual incidence rates per 100,000 patient-years and comparison against matched unexposed populations. FDA Sentinel surveillance methods are described here.

A Sentinel analysis evaluating sudden hearing loss across the PDE5 inhibitor class estimated an incidence of approximately 1.3 cases per 100,000 patient-years, a rate consistent with background incidence of idiopathic sudden sensorineural hearing loss in middle-aged men, but without a clearly elevated ROR that would confirm causality. This finding illustrates why FAERS signals require Sentinel validation before driving label changes.

The European Medicines Agency (EMA) conducted its own periodic safety review of vardenafil through the EPAR (European Public Assessment Report) process. The EMA EPAR for Levitra confirms that the European label tracks the FDA label's major safety warnings, with minor differences in alpha-blocker interaction language reflecting regional prescribing patterns. EMA product information for Levitra is available via the EMA website.

The HealthRX Vardenafil Safety Assessment Framework

Before prescribing vardenafil, the HealthRX medical team applies a structured pre-prescription safety checklist derived from FDA label requirements, FAERS signal categories, and Princeton III Consensus stratification. The five-point framework:

1. Nitrate and sGC-stimulator screen. Any current nitrate use (including as-needed sublingual nitroglycerin) or riociguat use is an absolute contraindication. Ask specifically about amyl nitrite ("poppers"), which are not always disclosed voluntarily.

2. QT risk assessment. Review the medication list for Class IA and III antiarrhythmics, confirm absence of congenital long-QT syndrome, and check baseline ECG in men over 50 with structural heart disease.

3. Cardiac risk stratification (Princeton III). Assign low, intermediate, or high risk. Intermediate-risk patients should undergo a graded exercise stress test before vardenafil initiation. High-risk patients require stabilization before any PDE5 inhibitor use. Princeton III Consensus is indexed at PubMed.

4. CYP3A4 inhibitor review. Check for ritonavir (contraindicated), strong inhibitors requiring 2.5 mg dose ceiling, and moderate inhibitors requiring 5 mg dose ceiling.

5. Alpha-blocker co-administration. If the patient takes any alpha-blocker, start vardenafil at 5 mg and titrate based on hemodynamic response, not simply on efficacy.

Reporting Vardenafil Adverse Events

Patients and providers can report suspected adverse events through the FDA MedWatch program online at https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program or by calling 1-800-FDA-1088. Manufacturers are required to submit reports to FAERS, but voluntary provider and patient reports meaningfully expand the database for rare event detection.

Any report of sudden vision loss, sudden hearing loss, erection lasting more than 4 hours, or syncope should be submitted to MedWatch in addition to clinical management, because these events specifically contribute to ongoing pharmacovigilance for the PDE5 inhibitor class. FDA MedWatch reporting portal is here.